Autopsy report · NCT02343679

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

“No accrual due to rarity of disease.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Anne Beaven, MD

Sponsor type

University, hospital or other

Conditions

Hematologic Malignancies

Interventions

ceritinib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Dose-adjusted EPOCH-R in MYC Positive DLBCL
  “Poor accrual of eligible patients” (65% match in meaning)
• Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
  “Low accrual due to COVID-19 pandemic.” (64% match in meaning)
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (61% match in meaning)
• Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
  “Poor patient accrual” (60% match in meaning)
• Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
  “Unable to accrue patients at a reasonable rate” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.